Skip to content
Radiotherapy and oncology

Publications

2019

  1. Jääskeläinen, A, Jukkola, A, Haapasaari, KM, Auvinen, P, Soini, Y, Karihtala, P et al.. Cytoplasmic Mineralocorticoid Receptor Expression Predicts Dismal Local Relapse-free Survival in Non-triple-negative Breast Cancer. Anticancer Res. 2019;39 (11):5879-5890. doi: 10.21873/anticanres.13792. PubMed PMID:31704812 .
  2. Tiainen, L, Korhonen, EA, Leppänen, VM, Luukkaala, T, Hämäläinen, M, Tanner, M et al.. High baseline Tie1 level predicts poor survival in metastatic breast cancer. BMC Cancer. 2019;19 (1):732. doi: 10.1186/s12885-019-5959-8. PubMed PMID:31340773 PubMed Central PMC6657075.
  3. Jääskeläinen, A, Jukkola, A, Risteli, J, Haapasaari, KM, Karihtala, P. Elevated preoperative serum levels of collagen I carboxyterminal telopeptide predict better outcome in early-stage luminal-B-like (HER2-negative) and triple-negative subtypes of breast cancer. Tumour Biol. 2019;41 (5):1010428319847081. doi: 10.1177/1010428319847081. PubMed PMID:31122159 .
  4. Tiainen, L, Hämäläinen, M, Luukkaala, T, Tanner, M, Lahdenperä, O, Vihinen, P et al.. Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer. Clin Breast Cancer. 2019;19 (4):e522-e533. doi: 10.1016/j.clbc.2019.03.006. PubMed PMID:31029558 .
  5. Hosio, M, Urpilainen, E, Marttila, M, Hautakoski, A, Arffman, M, Sund, R et al.. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. Breast Cancer Res Treat. 2019;175 (3):741-748. doi: 10.1007/s10549-019-05185-0. PubMed PMID:30895533 PubMed Central PMC6534663.

Search PubMed

2018

Search PubMed

2017

Search PubMed

2016

  1. Tiainen, L, Tanner, M, Lahdenperä, O, Vihinen, P, Jukkola, A, Karihtala, P et al.. Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer. Anticancer Res. 2016;36 (12):6431-6438. doi: 10.21873/anticanres.11241. PubMed PMID:27919965 .
  2. Hakala, TT, Sand, JA, Jukkola, A, Huhtala, HS, Metso, S, Kellokumpu-Lehtinen, PL et al.. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. Int J Clin Oncol. 2016;21 (2):231-239. doi: 10.1007/s10147-015-0904-6. PubMed PMID:26410770 .

Search PubMed

2015

  1. Hakala, TT, Sand, JA, Jukkola, A, Huhtala, HS, Metso, S, Kellokumpu-Lehtinen, PL et al.. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. Int J Clin Oncol. 2016;21 (2):231-239. doi: 10.1007/s10147-015-0904-6. PubMed PMID:26410770 .

Search PubMed